Management of Cirrhosis

Initial Assessment and Risk Stratification

• The American Association for the Study of Liver Diseases recommends determining if the patient has compensated or decompensated cirrhosis, as this fundamentally changes management priorities, with decompensated cirrhosis carrying a median survival of approximately 1 year without transplantation and requiring immediate transplant evaluation 1
• Calculate the MELD-Na score to assess mortality risk and transplant priority, with scores ≥15 warranting transplant referral, and scores ≥22 indicating significant mortality risk requiring urgent evaluation 1
• Perform diagnostic paracentesis immediately in any patient with new-onset ascites or clinical deterioration to rule out spontaneous bacterial peritonitis (SBP), sending fluid for cell count with differential, albumin, culture, total protein, and Gram stain 2, 1

Etiology-Specific Treatment

• Treat the underlying cause aggressively, as this is the only way to potentially reverse early cirrhosis and prevent progression, with antiviral therapy for hepatitis C, abstinence support and psychopharmacological therapy for alcohol-use disorder, and weight loss/metabolic management for nonalcoholic steatohepatitis 3
• Even after successful viral eradication (SVR in hepatitis C), continue monitoring for cirrhosis complications and hepatocellular carcinoma as the cirrhosis persists 3

Ascites Management

• Implement dietary sodium restriction to 5-6.5 g daily, which translates to a no-added-salt diet with avoidance of precooked meals, and provide nutritional counseling on sodium content 2, 3
• For first presentation of moderate ascites, initiate spironolactone monotherapy at 100 mg once daily, titrating up to 400 mg as needed based on response and tolerability 2, 3
• For recurrent severe ascites or hospitalized patients requiring faster diuresis, use combination therapy with spironolactone 100 mg plus furosemide 40 mg daily, increasing doses proportionally (up to spironolactone 400 mg and furosemide 160 mg) to maintain the 100:40 ratio 2, 3
• Monitor closely for adverse events, nearly half of patients require dose reduction or discontinuation due to electrolyte abnormalities, renal dysfunction, or hypotension 2, 3
• Fluid restriction to 1-1.5 L/day should only be used in patients with severe hyponatremia (sodium <125 mmol/L) who are clinically hypervolemic, routine fluid restriction is not necessary for most cirrhotic patients with ascites 2, 3, 4

Spontaneous Bacterial Peritonitis Prophylaxis

• Provide primary prophylaxis with norfloxacin 400 mg daily, ciprofloxacin 500 mg daily, or co-trimoxazole 800/160 mg daily to patients with ascitic fluid protein <1.5 g/dL, though antibiotic choice should be guided by local resistance patterns 2, 3
• All patients recovering from an episode of SBP require secondary prophylaxis indefinitely with the same antibiotic regimens to prevent recurrence 2, 3

Hepatic Encephalopathy Management

• Initiate lactulose 15-30 mL orally 2-3 times daily, titrating to achieve 2-3 soft bowel movements per day, this reduces mortality and prevents recurrence 1
• Aggressively identify and treat precipitants, infection, constipation, gastrointestinal bleeding, electrolyte abnormalities, and offending medications 1
• Add rifaximin 550 mg twice daily if recurrent episodes occur despite lactulose therapy 1
• Do not restrict dietary protein, target 1.2-1.5 g/kg/day using dry or ideal body weight, and consider branched-chain amino acid supplementation 1

Variceal Bleeding Prevention

• Use beta-blockers cautiously in advanced decompensation as they may compromise renal function and hemodynamic stability 3
• For acute variceal hemorrhage, initiate vasoactive drugs immediately when bleeding is suspected, continuing for 2-5 days after endoscopic hemostasis 3

Hepatorenal Syndrome and Acute Kidney Injury

• Immediately discontinue all diuretics, NSAIDs, ACE inhibitors, beta-blockers, and nephrotoxic drugs when acute kidney injury develops 1
• Expand plasma volume with albumin 1 g/kg (up to 100 g) over 2-4 hours if hypovolemia is suspected 1
• Target mean arterial pressure of 65 mmHg, using norepinephrine as first-line vasopressor if hypotension persists despite volume resuscitation 1, 4

Medications to Avoid

• Absolutely avoid NSAIDs as they precipitate renal failure in cirrhotic patients 3
• Avoid aminoglycosides and other nephrotoxic drugs 3
• ACE inhibitors aggravate hypotension and are not clinically useful 4

Monitoring in Decompensated Cirrhosis

• Monitor complete blood count, comprehensive metabolic panel, and liver function tests at least twice weekly initially, then weekly once stable 1
• Assess daily weight, vital signs, mental status, intake/output, and volume status 1

Transplant Evaluation

• Refer all patients with decompensated cirrhosis for liver transplant evaluation immediately, as transplantation is the only definitive cure and median survival without transplant is approximately 1 year 1
• Discuss prognosis and treatment goals with patient and family, ensure advance directives are in place, and consider palliative care consultation if transplant is not feasible 1

Management of Hypotension in Cirrhosis – Evidence‑Based Recommendations

Immediate Hemodynamic Assessment

• Perform an early baseline assessment of volume status, tissue perfusion, and cardiovascular function in all hypotensive cirrhotic patients to differentiate hypovolemia, septic shock, and cirrhosis‑related circulatory dysfunction. 5
• Use bedside transthoracic echocardiography to evaluate intravascular volume and cardiac performance, guiding fluid and vasopressor decisions. 6
• Consider invasive arterial and central venous pressure monitoring for precise cardiac output assessment and titration of vasopressors, especially when high‑dose support is required. 5
• Systematically search for precipitants such as gastrointestinal bleeding, spontaneous bacterial peritonitis, sepsis, hepatorenal syndrome, and recent use of beta‑blockers or diuretics. 7

Volume Resuscitation Strategy

• Prefer balanced crystalloids (e.g., lactated Ringer’s) and/or albumin over normal saline for intravascular volume expansion, because cirrhotic patients distribute fluids preferentially to the non‑central compartment. 5
• Administer albumin 1 g/kg (maximum 100 g) over 2–4 h when hypovolemia is suspected, particularly in the setting of acute kidney injury or suspected hepatorenal syndrome. 8

Vasopressor Therapy

• Initiate norepinephrine as the first‑line vasopressor together with appropriate fluid resuscitation to maintain organ perfusion. 6
• Target a mean arterial pressure (MAP) of 65 mmHg while continuously evaluating end‑organ perfusion; recognize the hyperdynamic circulation (high cardiac output, low systemic vascular resistance) typical of cirrhosis. 5
• Add vasopressin as a second‑line agent when escalating norepinephrine doses, addressing documented vasopressin deficiency in cirrhosis‑related shock. 6
• Avoid dopamine, which has been shown to be inferior to other vasopressor combinations in this population. 9

Management of Refractory Shock

• Screen for relative adrenal insufficiency or empirically start hydrocortisone 50 mg IV every 6 h (or a continuous 200‑mg infusion) in patients requiring high‑dose vasopressors. 5
• Relative adrenal insufficiency occurs in ~49 % of acutely decompensated cirrhotics and is linked to higher 90‑day mortality (26 % vs 10 %). 6

Hepatorenal Syndrome (HRS)‑Specific Management

• Immediately discontinue diuretics, NSAIDs, ACE inhibitors, beta‑blockers, and other nephrotoxic agents when AKI develops in the context of hypotension. 8
• Use terlipressin 0.85–1 mg IV every 4–6 h combined with albumin as first‑line therapy for HRS; this regimen reverses HRS and improves survival. 9
• When terlipressin is unavailable, employ octreotide (100–200 µg SC TID) plus midodrine (titrated to 12.5 mg PO TID) with albumin; this approach is suitable for non‑ICU settings. 9
• In ICU patients, norepinephrine infusion plus albumin has demonstrated ~83 % success in reversing type 1 HRS in pilot studies. 9

Infection Management

• Start broad‑spectrum antibiotics immediately on suspicion of infection; bacterial infections are present in >50 % of acute decompensation episodes and independently predict bleeding failure and mortality. 7
• Prefer ceftriaxone 1 g IV daily for up to 7 days in advanced cirrhosis or in patients already on quinolone prophylaxis, given the high rate of quinolone‑resistant organisms. 7
• Avoid aminoglycosides because of their heightened nephrotoxic risk in cirrhotic patients. 8

Specific Clinical Scenarios

• Large‑Volume Paracentesis: Give albumin 6–8 g per litre of ascitic fluid removed when >5 L is extracted to prevent paracentesis‑induced circulatory dysfunction. 8
• Gastrointestinal Bleeding: Apply a restrictive transfusion strategy (target hemoglobin 7–9 g/dL). Initiate vasoactive agents (terlipressin, somatostatin, or octreotide) immediately before endoscopy and continue for 3–5 days. Avoid starch solutions for volume replacement. 7
• Spontaneous Bacterial Peritonitis: Administer albumin 1.5 g/kg at diagnosis and 1 g/kg on day 3 together with antibiotics to prevent renal failure and improve survival. 8

Monitoring Parameters

• Continuously monitor vital signs, urine output, mental status, and volume status throughout resuscitation.
• Use lactate clearance as a surrogate for adequacy of tissue perfusion and resuscitation effectiveness. 8
• Vigilantly watch for complications: pulmonary edema from albumin, digital ischemia from vasopressin, and tachyarrhythmias from vasopressor therapy. 6

Common Pitfalls

• Do not use normal saline for volume resuscitation; balanced crystalloids are preferred to avoid hyperchloremic metabolic acidosis. 5

All statements are supported by the cited references indicated in brackets.